Table 4.
Clinical, functional, and dosimetric factors on RP
| Characteristics | RP | No-RP | P |
|---|---|---|---|
| Age Mean (range) |
58.5 (38–70) |
59 (40–70) |
0.83 |
| Gender (Male/Female) |
25/13 |
23/19 |
0.36 |
| KPS Mean (range) |
90.5 (80–100) |
91.9 (80–100) |
0.40 |
| AJCC clinical stage (IIIA/ IIIB) |
18/20 |
17/25 |
0.53 |
| Histology (AD/SQ/LA/OT) |
17/20/1/0 |
14/23/2/3 |
0.30 |
| Tumor site (UM/LO) |
29/9 |
28/14 |
0.34 |
| Comorbidity (COPD/CA/DI) |
2/1/0 |
5/2/1 |
0.80 |
| Smoking history (NO/CU) |
20/18 |
14/28 |
0.81 |
| Chemotherapy (Yes/ No) |
30/8 |
26/16 |
0.10 |
| V20 Mean (range) |
38.2 (8.6-63.3) |
29.6 (8.9-60.2) |
0.02 |
| V30 Mean (range) |
33.9 (7.9-48.5) |
25.6 (6.6-51.0) |
0.001 |
| DLCO (%) Mean (range) |
87.4 (61.3-99.4) |
85.7 (65.4-98.7) |
0.53 |
| FEV1 (%) Mean (range) |
86.3 (63.6-99.0) |
83.4 (66.6-99.4) |
0.24 |
| FVC (%) Mean (range) |
90.9 (75.6-99.6) |
89.5 (74.3-99.4) |
0.38 |
| MLD Mean (range) |
16.7 (5.9-25.6) |
14.0 (7.9-21.3) |
0.008 |
| Weight loss ≥ 5% (Yes/ No) | 18/20 | 11/31 | 0.0 |
Abbreviations: KPS: Karnofsky performance status, AD: Adenocarcinoma, SQ: Squamous cell, LA: Large cell carcinoma, OT: Other, UM: Upper&middle, LO: Lower, COPD: chronic obstructive pulmonary disease, CA: Cardiovascular disease, DI: diabetes, NO: Nonsmoker, CU: Current or ex smoker, V20: Percentage of irradiated lung volume exceeding 20 Gy, V30: Percentage of irradiated lung volume exceeding 30 Gy, DLCO: Diffusion capacity for carbon monoxide, FEV1: Forced expiratory volume at 1 second, FVC: Forced vital capacity, MLD: mean lung dose.